Small Airway Obstruction in Asthma, COPD, ACOS

Study Overview
=================
Brief Summary
-----------------
This study was designed as retrospective chart review to test our hypothesis whether there are the differences in inflammatory and anti-inflammatory mediators between asthmatic and ACOS patients with small airway obstruction, and COPD

Detailed Description
-----------------
The data including spirometry, lung volume, impulse oscillometry, sputum data, demographic characters within 6 months are collected for later analysis. Sputum supernatants and cytospins are used to determine inflammatory and anti-inflammatory responses in those patients.

Official Title
-----------------
Comparative Study on Sputum Anti-inflammatory Mediators in Patients With Asthma or Asthma and COPD Overlap (ACOS) Syndrome, and COPD

Conditions
-----------------
Asthma, COPD, Asthma-COPD Overlap Syndrome

Intervention / Treatment
-----------------
* Other: No any intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physician-diagnosed asthma, ACO, and COPD Their spirometric, IOS, lung volume, demographic data and sputum samples are available Exclusion Criteria: Concomitant diseases requiring immunosuppressive therapy Being on treatments with NSAIDs, macrolides, statins

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Asthma with SAO+<br>Asthmatic patients with RV/TLC > or = 40 | Other: No any intervention<br>* No any intervention is applied to any groups in this study<br>|
| Asthma with SAO-<br>Asthmatic patients with RV/TLC < 40 | Other: No any intervention<br>* No any intervention is applied to any groups in this study<br>|
| ACO<br>Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD) | Other: No any intervention<br>* No any intervention is applied to any groups in this study<br>|
| COPD<br>Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD) | Other: No any intervention<br>* No any intervention is applied to any groups in this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lipoxin A4, , | Lipoxin A4 is measured in sputum supernatants by ELISA | 1 day (single time point) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-33 | IL-33 is measured in sputum supernatants by ELISA | 1 day (single time point) | 
| Thymic stromal lymphopoietin (TSLP) | TSLP is measured in sputum supernatants by ELISA | 1 day (single time point) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Small airway obstruction, Asthma, COPD, ACOS